GURIOLI, GIULIA
GURIOLI, GIULIA
EDU - DIPARTIMENTO DI SCIENZE DELL'EDUCAZIONE "GIOVANNI MARIA BERTIN"
Collaboratori
IMPROVISE AND COMPOSE IN INCLUSIVE SCHOOL WITH REFLEXIVE INTERACTION AND THE MIROR PLATFORM
In corso di stampa Addessi, Anna Rita; Chiesa, Chiara; Gurioli, Giulia
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer
2025 Brighi, N.; Wetterskog, D.; Vainauskas, O.; Orlando, F.; Ciani, Y.; Gurioli, G.; Conteduca, V.; Casadei, C.; Lolli, C.; Giunta, E. F.; Bleve, S.; Basso, U.; Pierantoni, F.; Fornarini, G.; Mosca, A.; Nicodemo, M.; Banna, G. L.; Ulivi, P.; Wingate, A.; Cremaschi, P.; De Giorgi, U.; Demichelis, F.; Attard, G.
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study
2024 Farolfi, A.; Gentili, N.; Testoni, S.; Rusconi, F.; Massa, I.; Danesi, V.; Altavilla, A.; Cursano, M. C.; Gurioli, G.; Burgio, S. L.; Ibarburu, G. H.; De Giorgi, U.
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
2023 Farolfi A.; Petracci E.; Gurioli G.; Tedaldi G.; Casanova C.; Arcangeli V.; Amadori A.; Rosati M.; Stefanetti M.; Burgio S.L.; Cursano M.C.; Lolli C.; Zampiga V.; Cangini I.; Schepisi G.; De Giorgi U,
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial
2023 Brighi, N.; Conteduca, V.; Gurioli, G.; Scarpi, E.; Cursano, M. C.; Bleve, S.; Lolli, C.; Schepisi, G.; Casadei, C.; Gianni, C.; Ulivi, P.; De Giorgi, U.
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
2022 Conteduca V.; Casadei C.; Scarpi E.; Brighi N.; Schepisi G.; Lolli C.; Gurioli G.; Toma I.; Poti G.; Farolfi A.; De Giorgi U.
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer
2022 Cursano, M. C.; Conteduca, V.; Scarpi, E.; Gurioli, G.; Casadei, C.; Gargiulo, S.; Altavilla, A.; Lolli, C.; Vincenzi, B.; Tonini, G.; Santini, D.; De Giorgi, U.
Uma experiência inclusiva com a plataforma MIROR e a LIS-Língua italiana de sinais em uma escola de ensino fundamenal I
2022 Gurioli, G.; Ferrari, L.; Addessi, A. R.
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
2020 Gurioli G.; Conteduca V.; Lolli C.; Schepisi G.; Gargiulo S.; Altavilla A.; Casadei C.; Scarpi E.; De Giorgi U.
Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial
2019 De Giorgi, U; Severi, S; Sarnelli, A; Sansovini, M; Monti, M; Gurioli, G; Nicolini, S; Scarpi, E; Casadei, C; Conteduca, V; Matteucci, F; Di Iorio, V; Amadori, D; Paganelli, G
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC)
2019 Conteduca, V; Wetterskog, D; Scarpi, E; Romanel, A; Gurioli, G; Jayaram, A; Lolli, C; Schepisi, G; Casadei, C; Menna, C; Wingate, A; Demichelis, F; De Giorgi, U; Attard, G
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management
2019 Casadei, C.; Schepisi, G.; Menna, C.; Chovanec, M.; Gurioli, G.; Galla, V.; Altavilla, A.; Marcellini, M.; Bellia, S. R.; Lolli, C.; Mego, M.; Rosti, G.; De Giorgi, U.
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide
2019 Lolli C.; De Lisi D.; Conteduca V.; Gurioli G.; Scarpi E.; Schepisi G.; Ravaglia G.; Menna C.; Farolfi A.; Altavilla A.; Burgio S.L.; Tonini G.; Santini D.; De Giorgi U.
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
2018 Conteduca V.; Gurioli G.; Rossi L.; Scarpi E.; Lolli C.; Schepisi G.; Farolfi A.; De Lisi D.; Galla V.; Burgio S.L.; Menna C.; Amadori A.; Losi L.; Amadori D.; Costi M.P.; De Giorgi U.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| IMPROVISE AND COMPOSE IN INCLUSIVE SCHOOL WITH REFLEXIVE INTERACTION AND THE MIROR PLATFORM | Addessi, Anna Rita; Chiesa, Chiara; Gurioli, Giulia | 9999-01-01 | - | Barcelona Publishers | 2.01 Capitolo / saggio in libro | - |
| Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer | Brighi, N.; Wetterskog, D.; Vainauskas, O.; Orlando, F.; Ciani, Y.; Gurioli, G.; Conteduca, V.; C...asadei, C.; Lolli, C.; Giunta, E. F.; Bleve, S.; Basso, U.; Pierantoni, F.; Fornarini, G.; Mosca, A.; Nicodemo, M.; Banna, G. L.; Ulivi, P.; Wingate, A.; Cremaschi, P.; De Giorgi, U.; Demichelis, F.; Attard, G. | 2025-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study | Farolfi, A.; Gentili, N.; Testoni, S.; Rusconi, F.; Massa, I.; Danesi, V.; Altavilla, A.; Cursano..., M. C.; Gurioli, G.; Burgio, S. L.; Ibarburu, G. H.; De Giorgi, U. | 2024-01-01 | ISCIENCE | - | 1.01 Articolo in rivista | Endometriosis.pdf |
| Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients | Farolfi A.; Petracci E.; Gurioli G.; Tedaldi G.; Casanova C.; Arcangeli V.; Amadori A.; Rosati M....; Stefanetti M.; Burgio S.L.; Cursano M.C.; Lolli C.; Zampiga V.; Cangini I.; Schepisi G.; De Giorgi U, | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | fonc-13-1221096.pdf; Table_1 .docx |
| Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial | Brighi, N.; Conteduca, V.; Gurioli, G.; Scarpi, E.; Cursano, M. C.; Bleve, S.; Lolli, C.; Schepis...i, G.; Casadei, C.; Gianni, C.; Ulivi, P.; De Giorgi, U. | 2023-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | main (1).pdf; 1-s2.0-S2059702923012772-mmc1.docx |
| Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide | Conteduca V.; Casadei C.; Scarpi E.; Brighi N.; Schepisi G.; Lolli C.; Gurioli G.; Toma I.; Poti ...G.; Farolfi A.; De Giorgi U. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | aseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer.pdf |
| Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer | Cursano, M. C.; Conteduca, V.; Scarpi, E.; Gurioli, G.; Casadei, C.; Gargiulo, S.; Altavilla, A.;... Lolli, C.; Vincenzi, B.; Tonini, G.; Santini, D.; De Giorgi, U. | 2022-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | Grade group system.pdf |
| Uma experiência inclusiva com a plataforma MIROR e a LIS-Língua italiana de sinais em uma escola de ensino fundamenal I | Gurioli, G.; Ferrari, L.; Addessi, A. R. | 2022-01-01 | - | APPRIS | 2.01 Capitolo / saggio in libro | - |
| Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide | Gurioli G.; Conteduca V.; Lolli C.; Schepisi G.; Gargiulo S.; Altavilla A.; Casadei C.; Scarpi E....; De Giorgi U. | 2020-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial | De Giorgi, U; Severi, S; Sarnelli, A; Sansovini, M; Monti, M; Gurioli, G; Nicolini, S; Scarpi, E;... Casadei, C; Conteduca, V; Matteucci, F; Di Iorio, V; Amadori, D; Paganelli, G | 2019-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC) | Conteduca, V; Wetterskog, D; Scarpi, E; Romanel, A; Gurioli, G; Jayaram, A; Lolli, C; Schepisi, G...; Casadei, C; Menna, C; Wingate, A; Demichelis, F; De Giorgi, U; Attard, G | 2019-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management | Casadei, C.; Schepisi, G.; Menna, C.; Chovanec, M.; Gurioli, G.; Galla, V.; Altavilla, A.; Marcel...lini, M.; Bellia, S. R.; Lolli, C.; Mego, M.; Rosti, G.; De Giorgi, U. | 2019-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide | Lolli C.; De Lisi D.; Conteduca V.; Gurioli G.; Scarpi E.; Schepisi G.; Ravaglia G.; Menna C.; Fa...rolfi A.; Altavilla A.; Burgio S.L.; Tonini G.; Santini D.; De Giorgi U. | 2019-01-01 | THE PROSTATE | - | 1.01 Articolo in rivista | - |
| Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer | Conteduca V.; Gurioli G.; Rossi L.; Scarpi E.; Lolli C.; Schepisi G.; Farolfi A.; De Lisi D.; Gal...la V.; Burgio S.L.; Menna C.; Amadori A.; Losi L.; Amadori D.; Costi M.P.; De Giorgi U. | 2018-01-01 | BMC CANCER | - | 1.01 Articolo in rivista | - |